The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Orphan Drugs for Adults Market Research Report 2024
Synopsis
Orphan drugs for adults refer to medications that are specifically developed and approved for the treatment of rare diseases or conditions in adult populations. These drugs are designed to address medical needs in adult patients who have limited treatment options due to the rarity of their conditions.
Global Orphan Drugs for Adults market is projected to reach US$ 106140 million in 2029, increasing from US$ 55670 million in 2022, with the CAGR of 9.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orphan Drugs for Adults market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Orphan Drugs for Adults market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Orphan Drugs for Adults report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Orphan drugs for adults refer to medications that are specifically developed and approved for the treatment of rare diseases or conditions in adult populations. These drugs are designed to address medical needs in adult patients who have limited treatment options due to the rarity of their conditions.
Global Orphan Drugs for Adults market is projected to reach US$ 106140 million in 2029, increasing from US$ 55670 million in 2022, with the CAGR of 9.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orphan Drugs for Adults market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Orphan Drugs for Adults market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Orphan Drugs for Adults report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs for Adults Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oncology Drugs
1.2.3 Gastrointestinal Drugs
1.2.4 Neurology Drugs
1.2.5 Cardio-vascular Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Orphan Drugs for Adults Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs for Adults Market Perspective (2018-2029)
2.2 Orphan Drugs for Adults Growth Trends by Region
2.2.1 Global Orphan Drugs for Adults Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Orphan Drugs for Adults Historic Market Size by Region (2018-2023)
2.2.3 Orphan Drugs for Adults Forecasted Market Size by Region (2024-2029)
2.3 Orphan Drugs for Adults Market Dynamics
2.3.1 Orphan Drugs for Adults Industry Trends
2.3.2 Orphan Drugs for Adults Market Drivers
2.3.3 Orphan Drugs for Adults Market Challenges
2.3.4 Orphan Drugs for Adults Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs for Adults Players by Revenue
3.1.1 Global Top Orphan Drugs for Adults Players by Revenue (2018-2023)
3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2018-2023)
3.2 Global Orphan Drugs for Adults Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs for Adults Revenue
3.4 Global Orphan Drugs for Adults Market Concentration Ratio
3.4.1 Global Orphan Drugs for Adults Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs for Adults Revenue in 2022
3.5 Orphan Drugs for Adults Key Players Head office and Area Served
3.6 Key Players Orphan Drugs for Adults Product Solution and Service
3.7 Date of Enter into Orphan Drugs for Adults Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs for Adults Breakdown Data by Type
4.1 Global Orphan Drugs for Adults Historic Market Size by Type (2018-2023)
4.2 Global Orphan Drugs for Adults Forecasted Market Size by Type (2024-2029)
5 Orphan Drugs for Adults Breakdown Data by Application
5.1 Global Orphan Drugs for Adults Historic Market Size by Application (2018-2023)
5.2 Global Orphan Drugs for Adults Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Orphan Drugs for Adults Market Size (2018-2029)
6.2 North America Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Orphan Drugs for Adults Market Size by Country (2018-2023)
6.4 North America Orphan Drugs for Adults Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Orphan Drugs for Adults Market Size (2018-2029)
7.2 Europe Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Orphan Drugs for Adults Market Size by Country (2018-2023)
7.4 Europe Orphan Drugs for Adults Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs for Adults Market Size (2018-2029)
8.2 Asia-Pacific Orphan Drugs for Adults Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2018-2023)
8.4 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Orphan Drugs for Adults Market Size (2018-2029)
9.2 Latin America Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Orphan Drugs for Adults Market Size by Country (2018-2023)
9.4 Latin America Orphan Drugs for Adults Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs for Adults Market Size (2018-2029)
10.2 Middle East & Africa Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2018-2023)
10.4 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Detail
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Orphan Drugs for Adults Introduction
11.1.4 Abbvie Revenue in Orphan Drugs for Adults Business (2018-2023)
11.1.5 Abbvie Recent Development
11.2 Orpharma
11.2.1 Orpharma Company Detail
11.2.2 Orpharma Business Overview
11.2.3 Orpharma Orphan Drugs for Adults Introduction
11.2.4 Orpharma Revenue in Orphan Drugs for Adults Business (2018-2023)
11.2.5 Orpharma Recent Development
11.3 Amgen
11.3.1 Amgen Company Detail
11.3.2 Amgen Business Overview
11.3.3 Amgen Orphan Drugs for Adults Introduction
11.3.4 Amgen Revenue in Orphan Drugs for Adults Business (2018-2023)
11.3.5 Amgen Recent Development
11.4 Recordati
11.4.1 Recordati Company Detail
11.4.2 Recordati Business Overview
11.4.3 Recordati Orphan Drugs for Adults Introduction
11.4.4 Recordati Revenue in Orphan Drugs for Adults Business (2018-2023)
11.4.5 Recordati Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Orphan Drugs for Adults Introduction
11.5.4 Novartis Revenue in Orphan Drugs for Adults Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Orphan Drugs for Adults Introduction
11.6.4 Celgene Revenue in Orphan Drugs for Adults Business (2018-2023)
11.6.5 Celgene Recent Development
11.7 Amryt Pharma
11.7.1 Amryt Pharma Company Detail
11.7.2 Amryt Pharma Business Overview
11.7.3 Amryt Pharma Orphan Drugs for Adults Introduction
11.7.4 Amryt Pharma Revenue in Orphan Drugs for Adults Business (2018-2023)
11.7.5 Amryt Pharma Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Orphan Drugs for Adults Introduction
11.8.4 Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 GSK
11.9.1 GSK Company Detail
11.9.2 GSK Business Overview
11.9.3 GSK Orphan Drugs for Adults Introduction
11.9.4 GSK Revenue in Orphan Drugs for Adults Business (2018-2023)
11.9.5 GSK Recent Development
11.10 Bristol-Myers Squibb Company
11.10.1 Bristol-Myers Squibb Company Company Detail
11.10.2 Bristol-Myers Squibb Company Business Overview
11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Introduction
11.10.4 Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2018-2023)
11.10.5 Bristol-Myers Squibb Company Recent Development
11.11 Roche Holding
11.11.1 Roche Holding Company Detail
11.11.2 Roche Holding Business Overview
11.11.3 Roche Holding Orphan Drugs for Adults Introduction
11.11.4 Roche Holding Revenue in Orphan Drugs for Adults Business (2018-2023)
11.11.5 Roche Holding Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Detail
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Orphan Drugs for Adults Introduction
11.12.4 Sanofi Revenue in Orphan Drugs for Adults Business (2018-2023)
11.12.5 Sanofi Recent Development
11.13 Takeda
11.13.1 Takeda Company Detail
11.13.2 Takeda Business Overview
11.13.3 Takeda Orphan Drugs for Adults Introduction
11.13.4 Takeda Revenue in Orphan Drugs for Adults Business (2018-2023)
11.13.5 Takeda Recent Development
11.14 Pfizer
11.14.1 Pfizer Company Detail
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Orphan Drugs for Adults Introduction
11.14.4 Pfizer Revenue in Orphan Drugs for Adults Business (2018-2023)
11.14.5 Pfizer Recent Development
11.15 Vertex Pharmaceuticals
11.15.1 Vertex Pharmaceuticals Company Detail
11.15.2 Vertex Pharmaceuticals Business Overview
11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Introduction
11.15.4 Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2018-2023)
11.15.5 Vertex Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
